Correlation between PARP-1 immunoreactivity and cytomorphological features of parthanatos, a specific cellular death in breast cancer cells

European Journal of Histochemistry

Volumn 57, Issue 4, 2013, Pages 237-240

  Donizy, P ^a   Halon, A ^a   Surowiak, P ^a   Pietrzyk, G ^b   Kozyra, C ^c   Matkowski, R ^a,d  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b 4TH MILITARY HOSPITAL   (Poland)

^c WROCLAW UNIVERSITY OF ECONOMICS   (Poland)

^d Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

Author keywords

Breast cancer; Cell death; Immunohistochemistry; PARP 1; Parthanatos

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL DEATH; CELL NUCLEUS; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; NECROSIS; PATHOLOGY;

APOPTOSIS; BREAST NEOPLASMS; CELL DEATH; CELL NUCLEUS; FEMALE; HUMANS; MIDDLE AGED; NECROSIS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84888092842     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/ejh.2013.e35     Document Type: Article

References (26)

1. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011;105:1114-22.
2. Kiliańska ZM, Żołnierczyk J, We{ogonek}sierska-Ga{ogonek}dek J. Biological activity of poly(ADPribose) polymerase-1. Postepy Hig Med Dosw 2010;64:344-63.
3. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010;39:8-24.
4. Horton JK, Wilson SH. Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency. DNA Repair 2007;6:530-43.
5. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004;26:882-93.
6. Wang Y, Kim NS, Haince JF, Kang HC, David KK, Andrabi SA, et al. Poly(ADPribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal 2011;4:ra20.
7. Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol 2009;218:193-202.
8. Delettre C, Yuste VJ, Moubarak RS, Bras M, Lesbordes-Brion JC, Petres S, et al. AIFsh, a novel apoptosis-inducing factor (AIF) pro-apoptotic izoform with potential pathological relevance in human cancer. J Biol Chem 2006;281:6413-27.
9. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002;297:259-63.
10. Wang H, Yu SW, Koh DW, Lew J, Coombs C, Bowers W, et al. Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci 2004;24:10963-73.
11. Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 2005;12: n1463-7.
12. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004;16:663-9.
13. Galia A, Calogero AE, Condorelli R, Fraggetta F, La Corte A, Ridolfo F, et al. PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem 2012;56:e9.
14. Salemi M, Galia A, Fraggetta F, La Corte C, Pepe P, La Vignera S, et al. Poly (ADPribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue. Eur J Histochem 2013;57:e13.
15. Halon A, Materna V, Drag-Zalesinka M, Nowak-Markwitz E, Gansukh T, Donizy P, et al. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res 2011;17:511-8.
16. Halon A, Nowak-Markwitz E, Maciejczyk A, Pudelko M, Gansukh T, Györffy B, et al. Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res 2011;31:711-8.
17. Szczuraszek K, Halon A, Materna V, Mazur G, Wrobel T, Kuliczkowski K, et al. Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas. Anticancer Res 2011;31:2963-70.
18. Remmele W, Stegner HE. Recommen-dation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40.
19. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/proapoptotic dualrole proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002;511:145-78.
20. Fossati S, Cipriani G, Moroni F, Chiarugi A. Neither energy collapse nor transcription underline in vitro neurotoxicity of poly(ADP-ribose) polymerase hyper-activation. Neurochem Int 2007;50:203-10.
21. Moubarak RS, Yuste VJ, Artus C, Bouharrour A, Greer PA, Menissier-de Murcia J, et al. Sequential activation of poly(ADP-ribose) polymerase 1, calpains, and Bax is essential in apoptosis-inducing factor-mediated programmed necrosis. Mol Cell Biol 2007;27:4844-62.
22. Kanai M, Hanashiro K, Kim SH, Hanai S, Boulares AH, Miwa M, et al. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol 2007;9:1175-83.
23. Soldani C, Lazzè MC, Bottone MG, Tognon G, Biggiogera M, Pellicciari CE, et al. Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where? Exp Cell Res 2001;269:193-201.
24. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321-8.
25. von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, et al. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011;29:2150-7.
26. Rojo F, Garcia-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, et al. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 2012;23: 1156-64.